Association of CYP2C19 polymorphisms and lansoprazole-associated respiratory adverse effects in children.

[1]  N. Abraham.  Proton pump inhibitors: potential adverse effects , 2012, Current opinion in gastroenterology.

[2]  A. Goldsobel.  Lansoprazole for Children With Poorly Controlled Asthma: A Randomized Controlled Trial , 2012, Pediatrics.

[3]  P. Moayyedi,et al.  The risks of PPI therapy , 2012, Nature Reviews Gastroenterology &Hepatology.

[4]  V. Tolia.  Lansoprazole in the Treatment of Gastrooesophageal Reflux Disease in Children and Adolescents , 2005, Drugs.

[5]  D. Gagnon,et al.  Risk of community-acquired pneumonia in veteran patients to whom proton pump inhibitors were dispensed. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  E. Katz,et al.  Higher rate of bronchoalveolar lavage culture positivity in children with nonacid reflux and respiratory disorders. , 2011, The Journal of pediatrics.

[7]  Z. Tulassay,et al.  Update on the pharmacogenomics of proton pump inhibitors. , 2011, Pharmacogenomics.

[8]  D. McCarthy.  Adverse effects of proton pump inhibitor drugs: clues and conclusions , 2010, Current opinion in gastroenterology.

[9]  J. Nelson,et al.  Use of proton pump inhibitors and H2 blockers and risk of pneumonia in older adults: a population‐based case‐control study , 2010, Pharmacoepidemiology and drug safety.

[10]  L. Mody,et al.  Pharmacotherapy and the risk for community-acquired pneumonia , 2010, BMC geriatrics.

[11]  E. Juniper,et al.  Asthma Control Questionnaire in children: validation, measurement properties, interpretation , 2010, European Respiratory Journal.

[12]  G. Kearns,et al.  Impact of the CYP2C19*17 Allele on the Pharmacokinetics of Omeprazole and Pantoprazole in Children: Evidence for a Differential Effect , 2010, Drug Metabolism and Disposition.

[13]  M. Loeb,et al.  Meta‐analysis: proton pump inhibitor use and the risk of community‐acquired pneumonia , 2010, Alimentary pharmacology & therapeutics.

[14]  Current Opinion in Gastroenterology. Current world literature. , 2010, Current opinion in gastroenterology.

[15]  T. Marrie,et al.  Recurrent community-acquired pneumonia in patients starting acid-suppressing drugs. , 2010, The American journal of medicine.

[16]  M. Wallander,et al.  Acid-suppressive Drugs and Community-acquired Pneumonia , 2009, Epidemiology.

[17]  K. Altman,et al.  Unexpected consequences of proton pump inhibitor use , 2009, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[18]  R. Hubbard,et al.  Risk of community‐acquired pneumonia and the use of statins, ace inhibitors and gastric acid suppressants: a population‐based case–control study , 2009, Pharmacoepidemiology and drug safety.

[19]  N. Vakil.  Acid Inhibition and Infections Outside the Gastrointestinal Tract , 2009, The American Journal of Gastroenterology.

[20]  S. Hennessy,et al.  Proton-Pump Inhibitor Use and the Risk for Community-Acquired Pneumonia , 2008, Annals of Internal Medicine.

[21]  J. Gregor,et al.  Association between proton pump inhibitors and respiratory infections: a systematic review and meta-analysis of clinical trials. , 2008, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[22]  Jianwei Wang,et al.  A polymorphism in the NPPA gene associates with asthma , 2008, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[23]  L. Estborn,et al.  Occurrence of Community-Acquired Respiratory Tract Infection in Patients Receiving Esomeprazole , 2008, Drug safety.

[24]  J. Hallas,et al.  Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. , 2007, Archives of internal medicine.

[25]  Yoshiro Saito,et al.  Genetic Polymorphisms and Haplotypes of Major Drug Metabolizing Enzymes in East Asians and Their Comparison with Other Ethnic Populations , 2007 .

[26]  N. Anthonisen,et al.  Clinical trial of low-dose theophylline and montelukast in patients with poorly controlled asthma. , 2007, American journal of respiratory and critical care medicine.

[27]  J. Peters,et al.  Suppression of gastric acid secretion in patients with gastroesophageal reflux disease results in gastric bacterial overgrowth and deconjugation of bile acids , 2007, Journal of Gastrointestinal Surgery.

[28]  F. Manguso,et al.  Therapy With Gastric Acidity Inhibitors Increases the Risk of Acute Gastroenteritis and Community-Acquired Pneumonia in Children , 2006, Pediatrics.

[29]  Leif Bertilsson,et al.  A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants , 2006, Clinical pharmacology and therapeutics.

[30]  K. McColl,et al.  Review article: proton pump inhibitors and bacterial overgrowth , 2006, Alimentary pharmacology & therapeutics.

[31]  M. Numans,et al.  Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. , 2006, The Cochrane database of systematic reviews.

[32]  T. Ishizaki,et al.  Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. , 2005, Drug metabolism and pharmacokinetics.

[33]  L. Scott,et al.  Lansoprazole , 2012, Drugs.

[34]  C. Faure,et al.  Pharmacokinetics of Proton Pump Inhibitors in Children , 2005, Clinical pharmacokinetics.

[35]  Kyoichi Ohashi,et al.  Pharmacogenomics of proton pump inhibitors. , 2004, Pharmacogenomics.

[36]  Miriam C J M Sturkenboom,et al.  Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. , 2004, JAMA.

[37]  A. Thomson,et al.  The Clinical Importance of Proton Pump Inhibitor Pharmacokinetics , 2002, Digestion.

[38]  A. Blum,et al.  Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. , 1996, Gut.

[39]  G. Granneman,et al.  Determination of lansoprazole and five metabolites in plasma by high-performance liquid chromatography. , 1995, Journal of chromatography. B, Biomedical applications.

[40]  R. Hunt,et al.  Relationship between gastric secretion and infection. , 1987, Gut.